Astellas Recalls Mycamine Injection Vials Due to Labeling Error
Astellas Pharma US Inc is recalling 63,600 vials of Mycamine (micafungin sodium) for Injection due to a label error on the declared strength.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: The recall is classified as FDA Class II and involves a labeling error on declared strength, which fits the rubric criteria for minor labeling errors or low-risk contamination without reported serious injury.
Plain-English summary
Astellas Pharma US Inc is voluntarily recalling 63,600 vials of Mycamine (micafungin sodium) for Injection, 100 mg/vial. The recall is being conducted because of a labeling error regarding the declared strength of the medication. The affected product is a single-dose vial intended for intravenous use and is distributed nationwide.
The recall involves specific lots of the product: Lot F1700164 with an expiration date of 02/20 and Lot A000000220 with an expiration date of 06/20. The product is marketed by Astellas Pharma US, Inc. in Northbrook, IL, under NDC 0469-3211-10.
Healthcare providers and patients should check their inventory and medication records for these specific lot numbers and expiration dates. If the product is found, it should be held for return or disposal according to the recalling firm's instructions. This recall is classified as Class II by the FDA, indicating that use of the product could temporarily or medically reversibly affect health.
The recalled product
- Product
- MYCAMINE (MICAFUNGIN SODIUM)
- Brand
- MYCAMINE
- Manufacturer
- Astellas Pharma US Inc
- Category
- Drug — Antifungal Injection
- Hazard
- Affected units
- 63,600
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lots: F1700164 Exp. 02/20
- A000000220 Exp. 06/20
Distribution
Distributed nationwide across the United States.
Related recalls
Same manufacturer · Astellas Pharma US Inc
See all →- CriticalPrograf Tacrolimus Capsules Recall: Empty Capsules in Bottles
FDA (Drugs) · 2025-02-05
- SevereFDA Class I Recall: Astagraf XL Immunosuppressant Capsules May Be Empty
FDA (Drugs) · 2025-02-05
- ModerateAstellas Recalls Tarceva Tablets Due to Failed Dissolution Specifications
FDA (Drugs) · 2014-10-15
- SevereAstellas Recalls AmBisome Injection Lots Due to Sterility Concerns
FDA (Drugs) · 2013-07-31
Same hazard · mis labeling
See all →- ModerateMedline Trach Tube Kit Recalled for Component Labeling Discrepancy
FDA (Devices) · 2026-09-02
- ModerateAVID Medical Recalls Halyard Total Joint Kits for Latex Labeling Deficiency
FDA (Devices) · 2026-09-02
- ModerateOlympus Recalls PowerSeal Sealer Due to Incorrect Outer Box Labeling
FDA (Devices) · 2026-09-02
- HighSura Tanmen Ramen Noodles Recalled for Undeclared Fish Allergens
FDA (Food) · 2026-09-02
- SevereWhite Vein Advanced Alkaloids Chewable Tablets Recall for Excess Active Ingredient
FDA (Food) · 2026-09-02